These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Towards the Development of a Targeted Albumin-Binding Radioligand for Theranostic Applications: Synthesis, Radiolabelling and Preliminary In Vivo Studies
preprintsubmitted on 22.07.2020, 10:08 and posted on 22.07.2020, 12:59 by Cathryn H.S. Driver, Thomas Ebenhan, Jan Rijn Zeevaart, Roger Hunter, Iqbal Parker, Zoltan Szucs
GluCAB is a newly synthesised macrocyclic radioligand designed to bind in vivo to albumin (HSA) for the purpose of development as a dual-targeting oncological theranostic agent. Subsequent to its synthesis and 64Cu-radiolabelling, this radioligand has show a prolonged circulation time in healthy mice but with appropriate systemic clearance within 24 h. This radioligand meets the criteria to be further investigated for tumour targeting and uptake.